サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1435155

前部ぶどう膜炎治療薬市場：治療タイプ別、流通チャネル別-2024-2030年の世界予測

Anterior Uveitis Treatment Market by Treatment Type (Anti-Tumor Necrosis Factor Agents, Corticosteroids, Cycloplegic Agents), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 198 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
前部ぶどう膜炎治療薬市場：治療タイプ別、流通チャネル別-2024-2030年の世界予測
出版日: 2024年01月16日
発行: 360iResearch
ページ情報: 英文 198 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

前部ぶどう膜炎治療薬市場規模は、2023年に2億5,563万米ドルと推定され、2024年には2億7,728万米ドルに達し、CAGR 8.56%で2030年には4億5,431万米ドルに達すると予測されています。

前部ぶどう膜炎治療薬の世界市場

主な市場の統計
基準年[2023］ 2億5,563万米ドル
予測年[2024] 2億7,728万米ドル
予測年 [2030] 4億5,431万米ドル
CAGR（%） 8.56%
前部ぶどう膜炎治療薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは前部ぶどう膜炎治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、前部ぶどう膜炎治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-前部ぶどう膜炎治療薬市場の市場規模および予測は？

2-前部ぶどう膜炎治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-前部ぶどう膜炎治療薬市場における技術動向と規制の枠組みは？

4-前部ぶどう膜炎治療薬市場における主要ベンダーの市場シェアは？

5-前部ぶどう膜炎治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 眼感染症の有病率の上昇
      • コルチコステロイドや抗炎症薬などの薬剤の需要の増大
      • ぶどう膜炎治療に対する意識の高まり
    • 抑制要因
      • 費用が高く、医薬品に関する認識が限られている
    • 機会
      • 生物学的医薬品の調査会社の育成
      • ブドウ膜炎の新規薬剤および治療法の研究開発への支出の増加
    • 課題
      • コルチコステロイド治療に伴う副作用
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 前部ぶどう膜炎治療薬市場治療タイプ別

  • 抗腫瘍壊死因子剤
  • コルチコステロイド
  • サイクル麻痺剤
  • 免疫抑制剤

第7章 前部ぶどう膜炎治療薬市場：流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第8章 南北アメリカの前部ぶどう膜炎治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の前部ぶどう膜炎治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの前部ぶどう膜炎治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbbVie Inc.
    • Aciont Inc.
    • Ajanta Pharma Ltd
    • Aldeyra Therapeutics, Inc.
    • Alimera Sciences Inc.
    • American Academy of Ophthalmology
    • Amgen Inc.
    • Bausch & Lomb Incorporated
    • Cipla Ltd.
    • Clearside Biomedical, Inc.
    • Enzo Biochem Inc.
    • Eyegate Pharmaceuticals, Inc
    • HanAll Biopharma
    • Kiora Pharmaceuticals, Inc.
    • L V PRASAD EYE INSTITUTE
    • Lux Biosciences, Inc.
    • Novartis AG
    • Oculis SA
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Santen Pharmaceutical Co., Ltd.
    • Sirion Therapeutics, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Tarsier Pharma Ltd
    • Xoma Corporation
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTERIOR UVEITIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ANTERIOR UVEITIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTERIOR UVEITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTERIOR UVEITIS TREATMENT MARKET DYNAMICS
  • FIGURE 7. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 10. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ANTERIOR UVEITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. ANTERIOR UVEITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTERIOR UVEITIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTERIOR UVEITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY ANTI-TUMOR NECROSIS FACTOR AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY CYCLOPLEGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 11. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ANTERIOR UVEITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 101. ANTERIOR UVEITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. ANTERIOR UVEITIS TREATMENT MARKET LICENSE & PRICING
目次
Product Code: MRR-ED54C46E9121

[198 Pages Report] The Anterior Uveitis Treatment Market size was estimated at USD 255.63 million in 2023 and expected to reach USD 277.28 million in 2024, at a CAGR 8.56% to reach USD 454.31 million by 2030.

Global Anterior Uveitis Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 255.63 million
Estimated Year [2024] USD 277.28 million
Forecast Year [2030] USD 454.31 million
CAGR (%) 8.56%
Anterior Uveitis Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anterior Uveitis Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anterior Uveitis Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anterior Uveitis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Aciont Inc., Ajanta Pharma Ltd, Aldeyra Therapeutics, Inc., Alimera Sciences Inc., American Academy of Ophthalmology, Amgen Inc., Bausch & Lomb Incorporated, Cipla Ltd., Clearside Biomedical, Inc., Enzo Biochem Inc., Eyegate Pharmaceuticals, Inc, HanAll Biopharma, Kiora Pharmaceuticals, Inc., L V PRASAD EYE INSTITUTE, Lux Biosciences, Inc., Novartis AG, Oculis SA, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Sirion Therapeutics, Inc., Sun Pharmaceutical Industries Ltd., Tarsier Pharma Ltd, and Xoma Corporation.

Market Segmentation & Coverage

This research report categorizes the Anterior Uveitis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment Type
    • Anti-Tumor Necrosis Factor Agents
    • Corticosteroids
    • Cycloplegic Agents
    • Immunosuppressants
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anterior Uveitis Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anterior Uveitis Treatment Market?

3. What are the technology trends and regulatory frameworks in the Anterior Uveitis Treatment Market?

4. What is the market share of the leading vendors in the Anterior Uveitis Treatment Market?

5. Which modes and strategic moves are suitable for entering the Anterior Uveitis Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Anterior Uveitis Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of eye infections
      • 5.1.1.2. Growing demand for drugs such as corticosteroids and anti-inflammatory medications
      • 5.1.1.3. Growing awareness about the uveitis treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and limited awareness about the medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of research companies on biological drugs
      • 5.1.3.2. Rising expenditure on the research and development of novel drugs and treatments for Uveitis
    • 5.1.4. Challenges
      • 5.1.4.1. Side effect associated with corticosteroid treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Anterior Uveitis Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Anti-Tumor Necrosis Factor Agents
  • 6.3. Corticosteroids
  • 6.4. Cycloplegic Agents
  • 6.5. Immunosuppressants

7. Anterior Uveitis Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Americas Anterior Uveitis Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anterior Uveitis Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anterior Uveitis Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. AbbVie Inc.
    • 12.1.2. Aciont Inc.
    • 12.1.3. Ajanta Pharma Ltd
    • 12.1.4. Aldeyra Therapeutics, Inc.
    • 12.1.5. Alimera Sciences Inc.
    • 12.1.6. American Academy of Ophthalmology
    • 12.1.7. Amgen Inc.
    • 12.1.8. Bausch & Lomb Incorporated
    • 12.1.9. Cipla Ltd.
    • 12.1.10. Clearside Biomedical, Inc.
    • 12.1.11. Enzo Biochem Inc.
    • 12.1.12. Eyegate Pharmaceuticals, Inc
    • 12.1.13. HanAll Biopharma
    • 12.1.14. Kiora Pharmaceuticals, Inc.
    • 12.1.15. L V PRASAD EYE INSTITUTE
    • 12.1.16. Lux Biosciences, Inc.
    • 12.1.17. Novartis AG
    • 12.1.18. Oculis SA
    • 12.1.19. Pfizer Inc.
    • 12.1.20. Regeneron Pharmaceuticals, Inc.
    • 12.1.21. Santen Pharmaceutical Co., Ltd.
    • 12.1.22. Sirion Therapeutics, Inc.
    • 12.1.23. Sun Pharmaceutical Industries Ltd.
    • 12.1.24. Tarsier Pharma Ltd
    • 12.1.25. Xoma Corporation
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing